Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

relapsing chronic myelogenous leukemia

Known as: CML, relapsed, CML, relapsing, relapsed chronic myelocytic leukemia 
The reemergence of chronic myelogenous leukemia after a period of remission.
National Institutes of Health

Related topics

Related topics

17 relations
ABL1 geneAnemiaBCR-ABL Fusion GeneBone Marrow
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after…
Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Impact of climate change on snowpack in the Pyrenees: Horizontal spatial variability and vertical gradients
Summary In this study, snowpack series are modeled across the Pyrenees using data derived from the HIRHAM Regional Climate Model… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
The prognosis for patients with chronic myeloid leukemia (CML) in myeloid blast crisis (MBC) or lymphoid blast crisis (LBC… Expand
  • table 1
  • table 4
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients.
Advanced glycation endproduct (AGE) levels are elevated in renal failure patients and may contribute to the excessive… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.
Donor lymphocyte infusion (DLI) can produce durable remissions in patients with chronic myelogenous leukemia (CML) who have a… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
BACKGROUND The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of… Expand
Is this relevant?
1994
1994
Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia.
Recent studies suggest that the BCR-ABL gene plays a critical role in the pathogenesis of Ph+ chronic myeloid leukemia (CML). We… Expand
  • table 1
  • figure 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell…
Eight patients who had hematologic relapse of chronic myelogenous leukemia (CML) after undergoing allogeneic bone marrow… Expand
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE